Related Experiment Videos

Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production

R J Cherney¹, L Wang, D T Meyer

¹The DuPont Pharmaceutical Co., Experimental Station, Wilmington, DE 19880-0500, USA.

Bioorganic & Medicinal Chemistry Letters

|May 26, 1999

Abstract:

Several macrocyclic, hydroxamate derivatives were synthesized and evaluated as inhibitors of matrix metalloproteinases (MMPs) and tumour necrosis factor-alpha (TNF-alpha) production. These macrocycles are anti-succinate based inhibitors linked from P1 to P2'. A variety of functionality was installed at the P1-P2' linkage, which gave inhibitors that displayed excellent MMP inhibition and good TNF-alpha suppression.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Alphav and beta1 integrins regulate dynamic compression-induced proteoglycan synthesis in 3D gel culture by distinct complementary pathways.

Osteoarthritis and cartilage·2009

Intra-articular injection of tumor necrosis factor-alpha in the rat: an acute and reversible in vivo model of cartilage proteoglycan degradation.

Osteoarthritis and cartilage·2008

Biology of TACE inhibition.

Annals of the rheumatic diseases·2002

Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha.

Proceedings of the National Academy of Sciences of the United States of America·2001

Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.

Journal of medicinal chemistry·2001

Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.

Journal of medicinal chemistry·2001

See all related articles